NCT00170456View on ClinicalTrials.gov

Phase II Study of Range and Schedule of rPA Doses

PHASE2CompletedINTERVENTIONAL
Enrollment

415

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

January 31, 2007

Study Completion Date

February 28, 2007

Conditions
Prevention of Bacillus Anthracis (Anthrax) Infection
Interventions
BIOLOGICAL

rPA vaccine containing alhydrogel

Trial Locations (2)

Unknown

GDRU, Quintiles Ltd, London

CF48 4DR

Simbec Research Limited, Merthyr Tydfil

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

PharmAthene UK Limited

INDUSTRY

NCT00170456 - Phase II Study of Range and Schedule of rPA Doses | Biotech Hunter | Biotech Hunter